药理学
肾毒性
体内
阿霉素
血尿素氮
化学
顺铂
纳米凝胶
肌酐
一氧化氮
超氧化物歧化酶
肾功能
肾
医学
药物输送
氧化应激
内科学
生物化学
化疗
生物
有机化学
生物技术
作者
Norah F. Alqahtani,Mohammad Y. Alfaifi,Ali A. Shati,Serag Eldin I. Elbehairi,Reda F.M. Elshaarawy,Waleed M. Serag,Yasser A. Hassan,W.N. El-Sayed
标识
DOI:10.1016/j.ijbiomac.2023.128839
摘要
In this study, we aim to unveil the potential of itaconyl chondroitin sulfate nanogel (ICSNG) in tackling chronic kidney diseases triggered by the administration of CDDP and doxorubicin (Adriamycin, ADR). To that end, the new drug delivery system (ICSNG) was initially prepared, characterized, and loaded with the target drugs. Thereafter, the in-vivo studies were performed using five equally divided groups of 100 male Sprague-Dawley (SD) rats. Biochemical evaluation and immunohistochemistry studies have revealed the renal toxicity and the ameliorative effects of ICSNG on renal function. When ICSNG-based treatments were contrasted with the CDDP and ADR infected groups, they significantly increased paraoxonase-1 (PON-1), superoxide dismutase (SOD), catalase (CAT) and albumin activity and significantly decreased nitric oxide (NO), tumor necrosis factor alpha (TNF-α), creatinine, urea, and cyclooxygenase-2 (COX-2) activity (p < 0.001). The findings of the current study imply that ICSNG may be able to lessen renal inflammation and damage in chronic kidney disorders brought on by the administration of CDDP and ADR. Interestingly, according to the estimated selectivity indices, the ICSNG-encapsulated drugs have demonstrated superior selectivity for cancer MCF-7 cells, over healthy HSF cells, in comparison to the bare drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI